What factors drove the changes in Atea's revenue and profit?

What is the revenue and EPS growth rate for Atea year over year?

What is the market's earnings forecast for Atea next quarter?

What does Atea do and what are its main business segments?

What were the key takeaways from Atea’s earnings call?

Did Atea beat or miss consensus estimates last quarter?

What were the key takeaways from Atea's earnings call?

What is Atea's gross profit margin?

- **HCV Clinical Milestones**: Global Phase III enrollment complete (1,760+ patients); top-line results expected mid-2026 (C-BEYOND) and end-2026 (C-FORWARD).
- **HEV Expansion**: AT-587, a first-in-class HEV treatment, entering first-in-human trials mid-2026, targeting a $750M+ market with no approved therapies.
- **Financial Strength**: $301.8M cash runway through 2027; 2025 R&D investment (+22%) focused on HCV and HEV programs.
- **Commercial Readiness**: 75-person sales force; Phase II data shows 50% prescriber interest in new 8-week regimen with no food effect.

**【CEO Summary Section】**
- Completed enrollment for Phase III HCV trials (C-BEYOND and C-FORWARD) with over 1,760 patients globally. Top-line results expected mid-2026 for C-BEYOND and end-2026 for C-FORWARD.
- Expanded into HEV with AT-587, a first-in-class treatment for chronic HEV infection, targeting immunocompromised patients with no approved therapies. IND-enabling studies underway, with first-in-human trials expected mid-2026.
- Strong financial position with $301.8 million in cash, supporting operations through 2027.

**【CFO Financial Commentary】**
- 2025 R&D expenses increased 22% YoY to $142.3 million, driven by Phase III HCV trials and HEV program development.
- G&A expenses decreased 12% YoY to $31.5 million due to lower stock-based compensation and payroll expenses.
- Returned $25 million to shareholders via share repurchases in 2025.

**【Q&A Highlights】**
- **Enrollment Confidence**: Management confident in achieving enrollment targets for both C-BEYOND and C-FORWARD, with no cirrhotic patient enrollment issues.
- **Commercial Strategy**: 75-person sales force targeting 6,000 high-prescribing physicians. Phase II data shows 50% prescriber interest in using the regimen across all patient populations.
- **Pricing Dynamics**: Stable net pricing in HCV market; new regimen's convenience and efficacy may help maintain market share despite legacy pricing pressures.
- **HEV Market Potential**: Estimated $750 million to $1 billion annual opportunity for chronic HEV in U.S. and Europe, with orphan drug designation eligibility.


Atea Pharmaceuticals, Inc.(AVIR)-20260306-2025 Q4 Earnings call transcript

- **Phase III Progress**: On track for North American enrollment completion next month, with top-line results expected mid-2026.
- **Dual Mechanism Innovation**: Bemnifosbuvir inhibits both viral replication and assembly secretion, offering superior potency and resistance to NS5A mutations.
- **HEV Pipeline Expansion**: Two new candidates with 20x potency over ribavirin target unmet needs in immunocompromised patients.
- **Financial Strength**: $329.3 million cash runway through 2027, supporting Phase III execution and new program launches.
- **Strategic Differentiation**: No interaction with acid reducers, addressing 35% of HCV patients who use such medications.

**【Management Opening Remarks】**
- Jonae Barnes provided an overview of the call, highlighting the company's Phase III program progress, financial results, and new research findings. She emphasized the strong cash position of $329.3 million, providing runway through 2027.

**【CEO Summary Section】**
- Jean-Pierre Sommadossi highlighted the Phase III program for HCV treatment, with enrollment on track for completion in North America next month and top-line results expected mid-2026. He announced new dual mechanism of action data for bemnifosbuvir, showing inhibition of viral assembly and secretion, and the expansion of the pipeline to include two new HEV candidates.

**【CDO Financial Commentary】**
- Janet Hammond detailed the Phase III program's design, comparing the regimen to Epclusa, and highlighted data showing no interaction with proton pump inhibitors, a key differentiator. She also mentioned a virtual panel discussion on HCV treatment needs.

**【CMO Financial Commentary】**
- Maria Horga provided updates on the global Phase III trials (C-BEYOND and C-FORWARD), emphasizing the regimen's convenience and efficacy. Enrollment is expected to complete mid-2026, with results by late 2026.

**【CEO Dual Mechanism Update】**
- Jean-Pierre presented in vitro data showing bemnifosbuvir's dual mechanism of action, blocking both intracellular replication and viral assembly secretion, which may explain its higher potency compared to sofosbuvir.

**【CCO New Pipeline Expansion】**
- John Vavricka discussed the unmet need for HEV treatments in immunocompromised patients, presenting two new candidates with 20x higher potency than ribavirin. IND-enabling studies are ongoing.

**【CFO Financial Update】**
- Andrea Corcoran reported Q3 2025 financials: R&D expenses increased due to Phase III spending, G&A decreased due to lower stock-based compensation. The company completed a $25 million share repurchase program and maintains a strong cash position.

**【Q&A Highlights】**
- **Differentiation from Epclusa**: Janet Hammond emphasized the regimen's lack of interaction with acid reducers, a significant advantage over Epclusa. 
- **Genotype 3 Efficacy**: Jean-Pierre noted faster time to undetectable in genotype 3 patients, potentially due to the dual mechanism and historical in vitro potency against genotype 3.


Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript

- **Phase III Momentum**: Global trials on track with 98% cure rate in Phase II, targeting mid-2026 results. $3 billion market opportunity with 4 million untreated U.S. patients.
- **Prescriber Demand**: 76% of U.S. DAA prescribers prefer BEM/RZR, targeting half their patients. Consistent preference across 3 studies.
- **Financial Resilience**: $379.7 million cash runway through 2027. $25 million stock buyback executed, with 4.6 million shares retired.
- **Strategic Moves**: Added independent director Dr. Howard Berman to enhance governance and explore shareholder value initiatives.

**【CEO Opening Remarks】**
- **Clinical Progress**: Initiated global Phase III HCV program (C-BEYOND and C-FORWARD) with 880 patients each, targeting mid-2026 and end-2026 for top-line results. Phase II trial showed 98% SVR12 cure rate with 8-week treatment.
- **Market Opportunity**: $3 billion annual HCV market; 4 million untreated U.S. patients. Regimen aims to address unmet needs via short duration, low drug interactions, and test-and-treat model.
- **Financial Strength**: $379.7 million cash runway through 2027. Announced $25 million stock buyback and added independent director Dr. Howard Berman.

**【CFO Financial Commentary】**
- **Q2 2025 Financials**: R&D expenses decreased due to Phase III SUNRISE-3 completion. G&A expenses down 20% from Q2 2024 (lower stock-based comp). Cash balance remains strong at $379.7 million.
- **Shareholder Value**: Repurchased 4.6 million shares under $25 million buyback program. Projected cash runway through 2027 supports Phase III completion.

**【CFO & CEO Strategic Updates】**
- **Regulatory & Manufacturing**: Phase III program derisked with optimized manufacturing and clear regulatory pathway. Patent runway extends into 2030s.
- **Market Research**: 76% of U.S. DAA prescribers extremely likely to prescribe BEM/RZR, targeting ~50% of their patients. Consistent preference across 3 studies.

**【Q&A Highlights】**
- **Enrollment Progress**: C-BEYOND (U.S./Canada) and C-FORWARD (16 global countries) on track. Regulatory approvals faster in North America, but global sites actively enrolling.
- **Investigator Feedback**: High enthusiasm from investigators reflecting regimen's value proposition and patient interest.

Atea Pharmaceuticals, Inc. (AVIR) Q2 2025 Earnings Call Transcript

- **Phase III Launch Confirmed**: HCV regimen Phase III begins Q4 2024 with $454.7M cash runway to 2028.
- **Phase II Success**: 98% SVR12 cure rate validates 8-week treatment, best-in-class profile with no severe adverse events.
- **Strategic Momentum**: 20% workforce reduction ($15M savings), Evercore partnership advisory, and Board expansion with strategic advisor Arthur Kirsch.
- **FDA Alignment**: Agency-endorsed trial design with no additional requirements, supports 8-week regimen validation.
- **Cirrhotic Enrollment Flexibility**: Targeting 10-15% cirrhotic patients but maintaining flexibility to optimize label positioning.


**【CEO Summary Section】**
- Announced Phase III initiation for HCV regimen (bemnifosbuvir + ruzasvir) targeting Q4 2024 enrollment, with $454.7M cash runway extending to 2028.
- Highlighted 98% SVR12 cure rate in Phase II trial, positioning as potential best-in-class with 8-week treatment for non-cirrhotic patients.
- Strategic actions: retained Evercore for partnership exploration, implemented 20% workforce reduction ($15M annualized savings), and added Arthur Kirsch to Board for strategic guidance.

**【CFO Financial Commentary】**
- FY2024 R&D expenses: $131.7M (16% YoY increase) driven by Phase II/III trials; G&A flat at $42.5M.
- Cash balance: $454.7M as of Q4 2024, supporting Phase III execution with no external financing needs through 2027.
- Cost optimization: $15M annual savings from workforce reduction, 25% reduction in infrastructure spend.

**【Phase II Trial Results】**
- 98% SVR12 in treatment-compliant patients, 95% in all-intent-to-treat population, including 88% in cirrhotic patients.
- No drug-related severe adverse events; 100% bioclearance at end of treatment.
- Multi-scale modeling validates 8-week regimen efficacy, with 16-day viral clearance kinetics.

**【Phase III Program Design】**
- 2 open-label trials (n=800 each) comparing 8-week/12-week regimens vs. current standard of care.
- Enrollment targets: 10-15% cirrhotic patients globally, reflecting declining prevalence post-DAA era.
- Regulatory alignment: FDA-endorsed protocol with no additional requirements beyond Phase II data.

**【Q&A Highlights】**
- FDA guidance: no changes to trial design, supported open-label approach due to differentiated profile.
- Phase II follow-up: additional safety and adherence data to be presented at HCV conference in Q2 2025.
- Cirrhotic patient enrollment flexibility: target 10% but no strict caps, will adjust based on enrollment dynamics.


Atea Pharmaceuticals (AVIR)-6 Mar 25-2024 Q4 Earnings call transcript

Atea Pharmaceuticals (AVIR)-7 Nov 24-2024 Q3 Earnings call transcript

Atea Pharmaceuticals (AVIR)-7 Aug 24-2024 Q2 Earnings call transcript

Atea Pharmaceuticals (AVIR)-14 May 24-2024 Q1 Earnings call transcript

- **COVID-19 Clinical Momentum**: 1,400 patient enrollment in Sunrise-3, 98% SVR4 in HCV Phase II, and Fast Track designation for bemnifosbuvir highlight strong pipeline execution.
- **Financial Strength**: $578.1 million cash runway through 2026, disciplined expense growth aligned with clinical milestones.
- **Strategic Differentiation**: Protease inhibitor-free HCV regimen targets 40% of HIV/HCV co-infected patients, addressing $4-5 billion COVID-19 oral antiviral market gaps.
- **Operational Efficiency**: 80-employee team executing global trials with financial discipline, positioning for multibillion-dollar market opportunities.

**【CEO Summary Section】**
- Achieved significant clinical milestones in 2023, including enrollment of 1,400 patients in the Phase III Sunrise-3 trial for COVID-19, triggering the second interim analysis.
- Demonstrated 98% sustained virological response (SVR4) in the leading cohort of the HCV Phase II trial, with rapid viral kinetics supporting an 8-week regimen.
- Secured Fast Track designation for bemnifosbuvir for COVID-19 and advanced development of a second-generation protease inhibitor.
- Strong financial position with $578.1 million in cash, providing a runway through 2026.

**【CFO Financial Commentary】**
- Full-year 2023 R&D expenses increased due to clinical trial costs for Sunrise-3 and the HCV program.
- General and administrative expenses remained stable, with interest income rising from higher-yield investments.
- Reiterated financial discipline, with planned increases in 2024 expenses aligned with clinical and commercial readiness activities.

**【Q&A Highlights】**
- **COVID-19 Enrollment**: 75% of Sunrise-3 patients enrolled in the U.S., with strong winter wave-driven trends. Monotherapy cohort dominates due to drug-drug interaction risks with combination therapies.
- **HCV Differentiation**: Protease inhibitor-free regimen offers shorter (8-week) treatment duration, fewer side effects, and lower drug-drug interaction risk, addressing 40% of HIV/HCV co-infected patients' needs.
- **Commercial Opportunity**: Projected $4-5 billion global market for COVID-19 oral antivirals, with bemnifosbuvir targeting gaps in Paxlovid and molnupiravir safety profiles.
- **Risk Management**: Contingency plans for potential primary endpoint failure in Sunrise-3 include interim analyses and regulatory engagement.
- **Capital Allocation**: Prioritizes clinical trial completion and commercial readiness, with manufacturing investments contingent on regulatory approval.

Actual	-1.74	0.37	0.34	0.02	-0.34	1.34	-0.51	-0.38	-0.1	-0.41	-0.43	-0.34	-0.4	-0.47	-0.75	-0.48	-0.37	-0.4	-0.4	-0.44	-0.53	-0.57
Forecast	-0.3	0.245	-0.0542	0.0045	-0.0525	0.3249	-0.5825	-0.4916	-0.4122	-0.4439	-0.4763	-0.4699	-0.4624	-0.4323	-0.5211	-0.6629	-0.4267	-0.2887	-0.5033	-0.415	-0.415	-0.485
Surprise	-480.00%	+51.02%	+727.31%	+344.44%	-547.62%	+312.43%	+12.45%	+22.70%	+75.74%	+7.64%	+9.72%	+27.64%	+13.49%	-8.72%	-43.93%	+27.59%	+13.29%	-38.55%	+20.52%	-6.02%	-27.71%	-17.53%

Actual	0	48.60M	65.99M	60.39M	32.81M	192.18M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Forecast	0	45.00M	31.61M	58.00M	53.47M	85.73M	3.33M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Surprise	0.00%	+8.00%	+108.76%	+4.12%	-38.63%	+124.18%	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

AVIR

AVIR fundamentals

AVIR Q4 2025 Earnings

Earnings Call

You can ask Aime

AVIR

AVIR fundamentals

AVIR Q4 2025 Earnings

Earnings Call

AVIR Earnings Call Summary for Q4/20254:30 PM on Mar 5, 2026

AVIR Earnings Call Summary for Q3/20254:30 PM on Nov 12, 2025

AVIR Earnings Call Summary for Q2/20254:30 PM on Aug 7, 2025

AVIR Earnings Call Summary for Q1/20254:30 PM on May 13, 2025

AVIR Earnings Call Summary for Q4/20244:30 PM on Mar 6, 2025

You can ask Aime